MicroPort® MedBot™ JV’s R-ONE®, the World's First Dual-Finger Grasp Mimic Vascular Intervention Robot, Receives Approval in China

Shanghai, China, 26 February, 2024 — Recently, R-ONE® Vascular Intervention Robot (R-ONE®), agented by Cathbot, a joint venture in China between MicroPort® MedBot and French company Robocath S.A.S, received approval in China. R-ONE® is the world's first dual-finger grasp mimic vascular intervention robot that can reproduce manual operation.1 Its unique advantage in percutaneous coronary intervention is set to push cardiovascular interventional treatments into a new era of intelligence and precision.

Vascular intervention robots assisting in PCI have been proven safe and feasible in simple lesions since 2006. With advances in system technology and increased operator experience, there is a growing expectation for this technology to treat more complex lesions, redefining precision while reducing radiation exposure, and thereby improving treatment outcomes and safety.

The unique dual-finger grasp mimic technology of R-ONE® can mimic the operator's hand gestures - 0 to 360 degrees rotating and moving continuously - making it easier to go through the complex lesion and tortuous vasculature. Furthermore, millimeter stepping enhances the precision of the device’s positioning and the one-key locking/unlocking technology allows for secured access to the lesion during navigation. In Chinese clinical trials, R-ONE® was used in a variety of challenging and complex cases, including large angle twisted vessels, diffuse long lesions, calcified lesions, and sub-total occlusions. The procedures conducted in these trials achieved a clinical and technological success rate of 100%.1

With the progress of modern medicine, robotic treatment would enable better prognosis and postoperative quality of life.

R-ONE® has previously received CE mark and is the only commercialized CE-marked vascular robotic platform. Its architecture is compatible with mainstream interventional devices and cath labs currently used in the market. Additionally, Cathbot is actively developing 5G remote robotic PCI technology, providing a better solution to the unequal geographical distribution of specialist medical centers. In July 2023, this technology successfully performed a 5G remote robotic PCI over 2800 kilometers in China.

About MicroPort® MedBot

Founded in 2015, MicroPort® MedBot (Shanghai MicroPort MedBot Group Co., Ltd.; HKEX: 02252), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is currently the only surgical robot company in the world with businesses covering six promising subsectors of surgical robots including endoscopy, orthopedics, vascular intervention, natural orifice surgery, percutaneous puncture and medical aesthetics. MicroPort® MedBot is committed to meeting the growing demand for cutting-edge robotic surgery by integrating advanced research on robotics, control algorithms, electrical engineering, image-based navigation and precision imaging. MicroPort® MedBot provides comprehensive intelligent surgical solutions to lead the advancement of robotic surgery and shape the era of super intelligent surgery so patients everywhere can continue living better and longer lives.

More information is available at www.medbotsurgical.com/en


1. Data on File.